CN104619355A - 放射性药物络合物 - Google Patents

放射性药物络合物 Download PDF

Info

Publication number
CN104619355A
CN104619355A CN201380036807.4A CN201380036807A CN104619355A CN 104619355 A CN104619355 A CN 104619355A CN 201380036807 A CN201380036807 A CN 201380036807A CN 104619355 A CN104619355 A CN 104619355A
Authority
CN
China
Prior art keywords
complex
hopo
targeting moiety
thorium
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380036807.4A
Other languages
English (en)
Chinese (zh)
Inventor
汉内·特蕾泽·本格-汉森
奥拉夫·本杰明·瑞安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Algeta ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta ASA filed Critical Algeta ASA
Publication of CN104619355A publication Critical patent/CN104619355A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
CN201380036807.4A 2012-05-11 2013-05-13 放射性药物络合物 Pending CN104619355A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1208309.3 2012-05-11
GB201208309A GB201208309D0 (en) 2012-05-11 2012-05-11 Complexes
PCT/EP2013/059840 WO2013167755A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes

Publications (1)

Publication Number Publication Date
CN104619355A true CN104619355A (zh) 2015-05-13

Family

ID=46458687

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380036807.4A Pending CN104619355A (zh) 2012-05-11 2013-05-13 放射性药物络合物
CN201380035189.1A Pending CN104602716A (zh) 2012-05-11 2013-05-13 放射性药物络合物
CN201380036905.8A Pending CN104540530A (zh) 2012-05-11 2013-05-13 放射性药物络合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201380035189.1A Pending CN104602716A (zh) 2012-05-11 2013-05-13 放射性药物络合物
CN201380036905.8A Pending CN104540530A (zh) 2012-05-11 2013-05-13 放射性药物络合物

Country Status (9)

Country Link
US (3) US20150147272A1 (https=)
EP (3) EP2846843A1 (https=)
JP (3) JP6211066B2 (https=)
KR (3) KR20150092701A (https=)
CN (3) CN104619355A (https=)
CA (3) CA2873142A1 (https=)
GB (1) GB201208309D0 (https=)
HK (3) HK1206981A1 (https=)
WO (3) WO2013167756A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916731A (zh) * 2020-01-23 2023-04-04 瑞德兰有限责任公司 用于制备定制的放射性同位素溶液的系统和方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557601B2 (en) 2006-07-10 2013-10-15 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
WO2011025790A1 (en) 2009-08-24 2011-03-03 Lumiphore, Inc. Macrocyclic hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
US10821195B2 (en) * 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
SG10202009424TA (en) 2016-03-24 2020-11-27 Bayer Pharma AG Radio-pharmaceutical complexes
CN109689115A (zh) 2016-06-10 2019-04-26 拜耳制药股份公司 放射性药物配合物
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
EA202092044A1 (ru) * 2018-03-14 2021-03-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные рецепторы антигена против cd33 и их применения
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
JP7699542B2 (ja) * 2018-11-20 2025-06-27 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
USD885822S1 (en) 2018-12-14 2020-06-02 Whirlpool Corporation Food grinder
US20220125960A1 (en) 2019-02-21 2022-04-28 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
WO2020169538A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
WO2021013978A1 (en) 2019-07-25 2021-01-28 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
BR112022013678A2 (pt) * 2020-01-10 2022-11-16 Fusion Pharmaceuticals Inc Quelatos macrocíclicos e seus usos
CN116685602A (zh) * 2020-11-30 2023-09-01 先声创新公司 用于同种异体细胞治疗的通用嵌合抗原受体表达免疫细胞
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003123A2 (en) * 2004-06-25 2006-01-12 The European Community, Represented By The European Commission Radionuclides for medical use
WO2008085064A2 (en) * 2007-01-11 2008-07-17 Ge Healthcare As Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents
WO2011098611A2 (en) * 2010-02-12 2011-08-18 Algeta As Alpha-emitting complexes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US5624901A (en) * 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US7794691B2 (en) * 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
US8173800B2 (en) 2006-08-15 2012-05-08 The Regents Of The University Of California Luminescent macrocyclic lanthanide complexes
CN104710504B (zh) * 2009-07-22 2019-09-13 锕医药股份有限公司 用于制备放射性免疫缀合物的方法
JP2013515744A (ja) * 2009-12-24 2013-05-09 ルミフォア，インコーポレイテッド 放射性医薬品錯体
ES2496991T3 (es) * 2010-02-12 2014-09-22 Evonik Degussa Gmbh Composición cosmética que contiene éster parcial de poliglicerol
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003123A2 (en) * 2004-06-25 2006-01-12 The European Community, Represented By The European Commission Radionuclides for medical use
WO2008085064A2 (en) * 2007-01-11 2008-07-17 Ge Healthcare As Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents
WO2011098611A2 (en) * 2010-02-12 2011-08-18 Algeta As Alpha-emitting complexes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916731A (zh) * 2020-01-23 2023-04-04 瑞德兰有限责任公司 用于制备定制的放射性同位素溶液的系统和方法

Also Published As

Publication number Publication date
US20150110817A1 (en) 2015-04-23
KR20150092701A (ko) 2015-08-13
CA2873144C (en) 2021-03-16
CA2873144A1 (en) 2013-11-14
JP2015517483A (ja) 2015-06-22
GB201208309D0 (en) 2012-06-27
US9827336B2 (en) 2017-11-28
CA2873143A1 (en) 2013-11-14
EP2846844A1 (en) 2015-03-18
WO2013167756A1 (en) 2013-11-14
KR20150092702A (ko) 2015-08-13
KR20150092700A (ko) 2015-08-13
HK1206982A1 (en) 2016-01-22
WO2013167754A1 (en) 2013-11-14
CA2873142A1 (en) 2013-11-14
EP2846844B1 (en) 2020-04-01
CN104602716A (zh) 2015-05-06
EP2846842A1 (en) 2015-03-18
JP6219372B2 (ja) 2017-10-25
JP2015517482A (ja) 2015-06-22
EP2846843A1 (en) 2015-03-18
JP2015523326A (ja) 2015-08-13
WO2013167755A1 (en) 2013-11-14
HK1207307A1 (zh) 2016-01-29
JP6211066B2 (ja) 2017-10-11
HK1206981A1 (en) 2016-01-22
US20150104385A1 (en) 2015-04-16
CN104540530A (zh) 2015-04-22
US20150147272A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
CN104619355A (zh) 放射性药物络合物
US10682430B2 (en) Alpha-emitting complexes
Rasaneh et al. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer
CA2970841A1 (en) Radio-pharmaceutical complexes
Laznickova et al. Mono (pyridine-N-oxide) DOTA analog and its G1/G4-PAMAM dendrimer conjugates labeled with 177Lu: radiolabeling and biodistribution studies
CN119499408A (zh) 靶向gpc3的分子探针以及用途
Retzloff et al. Evaluation of [99mTc-(CO) 3-XY-Bombesin (7-14) NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma
Faintuch et al. Radiolabeled nano-peptides show specificity for an animal model of human PC3 prostate cancer cells
Persson et al. In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BAYER AG

Free format text: FORMER OWNER: ALGETA AS

Effective date: 20150710

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150710

Address after: Oslo, Norway

Applicant after: BAYER AG

Address before: Oslo, Norway

Applicant before: ALGETA A/S

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207307

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150513

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1207307

Country of ref document: HK